Oncternal Therapeutics, Inc. (ONCT)

Oncternal Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	1.15	0.79	1.49	4.32	3.38	2.43
Revenue Growth (YoY)	21.54%	-47.32%	-65.47%	27.85%	39.18%	-3.81%
Gross Profit	1.15	0.79	1.49	4.32	3.38	2.43
Selling, General & Admin	12.72	12.75	13.46	11.6	8.37	7.29
Research & Development	26.78	29.75	32.98	24.09	12.54	10.16
Other Operating Expenses	0	0	0	0	0	18.09
Operating Expenses	39.5	42.5	46.44	35.68	20.92	35.53
Operating Income	-38.35	-41.71	-44.95	-31.37	-17.54	-33.11
Other Expense / Income	-1.97	-2.24	-0.78	-0.03	-0.32	1.08
Pretax Income	-36.38	-39.48	-44.17	-31.33	-17.23	-34.19
Net Income	-36.38	-39.48	-44.17	-31.33	-17.23	-34.19
Shares Outstanding (Basic)	3	3	3	2	1	1
Shares Outstanding (Diluted)	3	3	3	2	1	1
Shares Change	1.13%	11.79%	6.65%	142.90%	96.58%	187.64%
EPS (Basic)	-12.26	-13.43	-16.80	-12.80	-17.00	-66.20
EPS (Diluted)	-12.26	-13.43	-16.80	-12.80	-17.00	-66.20
Free Cash Flow	-28.63	-32.16	-36.7	-26.59	-17.5	-16.75
Free Cash Flow Per Share	-9.68	-10.94	-13.96	-10.78	-17.23	-32.42
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-3331.89%	-5313.89%	-3016.58%	-726.91%	-519.76%	-1365.28%
Profit Margin	-3160.73%	-5029.17%	-2964.43%	-726.14%	-510.37%	-1409.81%
Free Cash Flow Margin	-2487.66%	-4097.32%	-2463.36%	-616.20%	-518.37%	-690.56%
EBITDA	-36.21	-39.31	-43.99	-31.16	-17.08	-34.1
EBITDA Margin	-3145.96%	-5007.01%	-2952.42%	-722.22%	-505.93%	-1406.02%
Depreciation & Amortization	0.17	0.17	0.18	0.17	0.15	0.09
EBIT	-36.38	-39.48	-44.17	-31.33	-17.23	-34.19
EBIT Margin	-3160.73%	-5029.17%	-2964.43%	-726.14%	-510.37%	-1409.81%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).